• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital.
Conclusions: The indications for intravenous thrombolysis in patients with IS should be strictly analysed so that the treatment is effective and safe especially in older patients, patients with greater severity of neurological symptoms and patients with old post-stroke lesions in baseline CT. PMID: 23986420 [PubMed - as supplied by publisher]
Source: Neurologia i Neurochirurgia Polska - September 3, 2013 Category: Neurology Authors: Sobolewski P, Sledzińska-Dźwigał M, Szczuchniak W, Hatalska-Żerebiec R, Grzesik M, Sobota A Tags: Neurol Neurochir Pol Source Type: research

Simultaneous thrombosis of 2 vascular territories: is thrombolytic therapy a better option?
We have read with great interest the article by Akyuz and colleagues in the American Journal of Emergency Medicine and congratulate them for their observation. Their case exemplifies the concurrent occurrence of ST-segment elevation myocardial infarction (STEMI) and posterior circulation stroke that was eventually managed with thrombolytic therapy. Simultaneous thrombosis of 2 distant vascular territories is a rare and complicated clinical scenario. In these instances, there is usually an underlying cause linking both thrombotic events rather than being a mere coincidence. We have previously described the myocardial infarc...
Source: The American Journal of Emergency Medicine - July 1, 2013 Category: Emergency Medicine Authors: Hesham R. Omar, Devanand Mangar, Enrico M. Camporesi Tags: Correspondence Source Type: research

The Elusive Golden Hour - A Multicenter Analysis of the Difficulties of Timely Intravenous Alteplase Treatment (P03.189)
CONCLUSIONS: Many factors contribute to delay in IV thrombolytic treatment in the acute stroke patient. In many patients when stabilization is needed or when the clinical presentation is confusing, it may be in the patient's best interest to delay thrombolytics until the situation is clarified. We must strive to identify causes of delay in our institutions to maintain maximum benefit of thrombolytic therapy for our patients.Disclosure: Dr. Sugg has received personal compensation for activities with Genetech as a speaker. Dr. Chaudhrey has nothing to disclose. Dr. Chen has nothing to disclose. Dr. Ehtisham has nothing to di...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sugg, R., Chaudhrey, B., Chen, S., Ehtisham, A., Summers, D., Rymer, M. Tags: P03 Cerebrovascular Disease III Source Type: research

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Abstract Intravenous recombinant human tissue plasminogen activato (rtPA, formulated as alteplase) is the primary therapy for acute ischaemic stroke by breaking down a clot of an occluded vessel. There are several randomised controlled trials and observational studies that support the use of rtPA to improve functional outcome following acute ischaemic stroke. However, thrombolytic therapy with rtPA can be associated with a number of complications. Many of the rtPA-related complications result from its thrombolytic action including bleeding (intracerebral and systemic haemorrhage), reperfusion injury with oedema, a...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Abstract Despite advances in the diagnosis and treatment of acute ischaemic stroke in the past two decades, stroke has remained the third cause of mortality and the single leading cause of disability worldwide. The immediate goal of acute ischaemic stroke therapy is to salvage the ischaemic penumbra through recanalisation of the occluded cerebral blood vessel. This is currently achieved through thrombolytics, which are pharmacological agents that can break up a clot blocking the flow of blood. To date, the only approved thrombolytic for treatment of acute ischaemic stroke is recombinant tissue plasminogen activato...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Chen R, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

Pages: 1  2  3  4  5